| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $128,822,136 ) (Continued on the next page) |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 000 | 5 | NIH | 2/2/2026 | $293,355 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076515 | Defining the interactions of senescent immune cells and skeletal cells | 000 | 5 | NIH | 3/20/2026 | $475,727 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DC014942 | The neurobiology of two distinct subtypes of neurodegenerative apraxia of speech: phenotypes of Alzheimer disease related 4-repeat tauopathies | 000 | 9 | NIH | 4/1/2026 | $643,670 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL172948 | Understanding and addressing the lack of and delayed screening for primary Aldosteronism | 000 | 2 | NIH | 5/18/2026 | $700,680 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276851 | Glioma intelligence from behind enemy lines | 000 | 4 | NIH | 5/5/2026 | $525,729 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR085016 | A novel, clinically expedient, AAV-based gene therapy for bone healing | 001 | 2 | NIH | 5/14/2026 | $24,010 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG056366 | Investigating Resistance and Resilience Mechanisms in Alzheimer’s Disease | 000 | 9 | NIH | 3/20/2026 | $779,639 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR085016 | A novel, clinically expedient, AAV-based gene therapy for bone healing | 000 | 2 | NIH | 2/5/2026 | $432,145 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | T32AR056950 | Musculoskeletal Research Training Program | 002 | 18 | NIH | 6/11/2026 | $550,271 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL145268 | Measuring arterial material properties using wave-based approaches with ultrasound and computational models | 000 | 8 | NIH | 4/24/2026 | $667,146 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31NS141217 | Identifying molecular mechanisms contributing to disease etiology and the neurological symptoms associated with pediatric DPD deficiency | 002 | 2 | NIH | 3/31/2026 | $576 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31NS141217 | Identifying molecular mechanisms contributing to disease etiology and the neurological symptoms associated with pediatric DPD deficiency | 001 | 2 | NIH | 3/11/2026 | $49,538 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK130854 | Role of SLCO3A1 in macrophage metabolite sensing and IBD | 000 | 4 | NIH | 1/14/2026 | $349,800 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK057061 | Calcium Dynamics in Interstitial Cells of Cajal | 000 | 25 | NIH | 1/19/2026 | $582,827 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA278050 | Mechanism and therapeutic opportunities of targeting the Tudor domain | 002 | 5 | NIH | 4/16/2026 | $51,437 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA278050 | Mechanism and therapeutic opportunities of targeting the Tudor domain | 001 | 5 | NIH | 1/28/2026 | $462,935 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS126227 | Seronegative Autoimmune Encephalopathies: Biomarker Discovery, Validation & Deep Phenotyping | 000 | 5 | NIH | 2/23/2026 | $397,500 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI184360 | Mechanisms of genetic variants in TH2 autoimmunity | 000 | 3 | NIH | 5/27/2026 | $594,931 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271503 | Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma | 001 | 4 | NIH | 4/16/2026 | $53,953 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271503 | Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma | 000 | 4 | NIH | 12/22/2025 | $485,587 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS113828 | Utilizing epidemiology, imaging and fluid biomarkers in MOG antibody-associated disease to inform prognosis, pathogenesis and therapeutics | 000 | 6 | NIH | 2/24/2026 | $638,605 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276005 | Aak1 to increase infiltration of adoptively transferred cells into solid tumors | 001 | 4 | NIH | 4/16/2026 | $45,762 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276005 | Aak1 to increase infiltration of adoptively transferred cells into solid tumors | 000 | 4 | NIH | 1/27/2026 | $411,873 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AA031167 | Multi-site DBS with precise timing control focusing on synaptic plasticity | 000 | 2 | NIH | 6/30/2026 | $543,111 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31CA301512 | Exploring LMTK2: A novel mediator of endocrine sensitivity in ER+ breast cancer | 001 | 1 | NIH | 4/9/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31CA301512 | Exploring LMTK2: A novel mediator of endocrine sensitivity in ER+ breast cancer | 000 | 1 | NIH | 4/9/2026 | $50,114 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA308978 | The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study | 000 | 1 | NIH | 3/9/2026 | $1,264,356 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA313650 | Accelerated Biological Aging and Immunosenescence as Drivers for Racial Disparities in Monoclonal Gammopathy of Undetermined Significance (MGUS) | 000 | 1 | NIH | 5/8/2026 | $558,016 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AA031965 | Neurosteroids and Alcohol Use Disorder | 000 | 2 | NIH | 6/30/2026 | $700,490 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA305931 | Radiomic phenotypes for invasive and advanced breast cancer | 000 | 1 | NIH | 5/7/2026 | $722,914 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK142296 | Autophagic Processes and Hepatocellular Steatosis | 000 | 1 | NIH | 2/18/2026 | $495,130 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3NS132128 | Hybrid approach for comprehensive mutation detection in a cell | 000 | 4 | NIH | 4/2/2026 | $562,212 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31DK146505 | Metabolism-mediated epigenetic regulation of hepatic stellate cell activation during liver fibrosis | 001 | 1 | NIH | 3/31/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31DK146505 | Metabolism-mediated epigenetic regulation of hepatic stellate cell activation during liver fibrosis | 000 | 1 | NIH | 3/31/2026 | $49,538 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31AI197938 | Designing Engineered Stem Cell Therapies for Immune-Mediated Demyelinating Diseases | 000 | 1 | NIH | 6/23/2026 | $50,114 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | RF1AG037491 | Understanding the role of TDP-43 in Alzheimer’s disease, FTLD and Related Disorders | 000 | 16 | NIH | 5/7/2026 | $3,391,515 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB039412 | Charge-sharing-correction for clinical multi-energy CT: Practical implementation on a whole-body photon-counting-detector CT scanner | 000 | 1 | NIH | 6/30/2026 | $620,179 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03EB039127 | Image-Based Analysis of Dose-Dependent Radiation Effects on the Myocardium following Cardiac Radioablation Therapy | 000 | 1 | NIH | 6/23/2026 | $80,200 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA300454 | Blood-based tumor and immune markers for risk stratification and monitoring treatment response in oligometastatic prostate cancer | 000 | 1 | NIH | 3/24/2026 | $667,710 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01MH143024 | SCH: Real-Time Engagement of Children for Individualizing Behavior Management with Wearables | 000 | 1 | NIH | 5/18/2026 | $301,092 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI195606 | Establishing the etiology of chronic placental villitis of unknown etiology | 000 | 1 | NIH | 3/30/2026 | $689,081 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI195565 | Regulation of target cell survival by TBK1 and IKKe | 000 | 1 | NIH | 2/23/2026 | $624,521 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA302685 | Improving Treatment Sensitivity through Syk using Novel Translational Models of Uveal Melanoma | 000 | 1 | NIH | 5/14/2026 | $415,000 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA299909 | Prospective Detection and Monitoring of NF1 peripheral nerve sheath tumors using cell-free DNA | 000 | 1 | NIH | 6/11/2026 | $688,661 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG097887 | Real world impact of glucagon-like peptide receptor agonist (GLP-1 RA) use on older adults | 000 | 1 | NIH | 3/13/2026 | $443,850 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL176479 | Quantitative and longitudinal assessment of diffuse pulmonary parenchymal disease using lung ultrasound surface wave elastography | 001 | 1 | NIH | 7/2/2026 | -$661,884 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL176479 | Quantitative and longitudinal assessment of diffuse pulmonary parenchymal disease using lung ultrasound surface wave elastography | 001 | 1 | NIH | 7/2/2026 | $661,884 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL176479 | Quantitative and longitudinal assessment of diffuse pulmonary parenchymal disease using lung ultrasound surface wave elastography | 000 | 1 | NIH | 6/25/2026 | $661,884 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK145433 | Acute Kidney Injury in Care Transitions: The ACT Pragmatic Trial | 000 | 1 | NIH | 3/3/2026 | $796,370 |
|
